AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04810429 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TMJ surgical arthroscopy
Description: TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
Study NCT04687423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-011
Description: FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
Study NCT05900570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urodynamic testing with and without pudendal nerve stimulation
Description: A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
Study NCT04932291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vafidemstat
Description: 1.2mg capsule
Study NCT04932291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study NCT05749302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-FAPI
Description: Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
Study NCT05669560 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PerioProtect ™= plastic tray +1.7% hydrogen peroxide
Description: Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
Study NCT05608122 — intervention group
Intervention type: OTHER
Intervention: Obervation
Description: This study is an observational study without any intervention
Study NCT04738695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)
Description: Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
Study NCT06443723 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USG, blood tests, waist, hip, height and blood pressure measurements
Description: MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5.
Study NCT05986227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab FOLFOX
Description: Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
Study NCT05986227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab FOLFOX
Description: Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
Study NCT04932915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
Study NCT04932915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
Study NCT05496244 — intervention group
Intervention type: DEVICE
Intervention: Laparoscopy
Description: Laparoscopic surgery
Study NCT05496244 — intervention group
Intervention type: DEVICE
Intervention: Robotic-assisted surgery
Description: Robotic-assisted surgery
Study NCT05775133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICG
Description: Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting.
Study NCT05368493 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI task
Description: Task fMRI (Simon) \[ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. \] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
Study NCT04913142 — intervention group
Intervention type: OTHER
Intervention: Fecal and oral samples
Description: oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
Study NCT06506539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placental Extract
Description: add placental extract gel as a local delivery drug in periodontal pocket
Study NCT05733728 — intervention group
Intervention type: OTHER
Intervention: any therapy suitable
Description: any therapy suitable
Study NCT06148025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus
Study NCT06148025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccine
Description: 0.5ml injected subcutaneously
Study NCT05478291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Appropriate diet and physical activity counselling to both groups. Supplementation with Vitamin D and oral Calcium-Doses of cholecalciferol (commercial name, Calcirol) 60,000 IU (sachets, dissolved in half glass milk) once per week for eight weeks for the intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer. After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated.If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 IU per day will be given as a maintenance dose. Equal doses of calcium carbonate (1gm per day, commercial name Calcal) will be given to both the groups.
Study NCT05978102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-7349
Description: Administered by intravenous infusion (IV)
Study NCT05978102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by intravenous infusion (IV)
Study NCT05978102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment（SoC）
Description: Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
Study NCT01420666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 325 mg, three tablets four times a day, orally, with food
Study NCT01420666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxigesic 325
Description: Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
Study NCT05124886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderately High Oxalate (MOx) Diet
Description: Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
Study NCT05124886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderately High Oxalate (MOx) Diet
Description: Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
Study NCT01420666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 97.5mg, three tablets four times a day, orally, with food
Study NCT01420666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, three tablets four times a day, orally, with food
Study NCT05705661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIGH FREQUENCY CHEST WALL OSCILLATION
Description: The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
Study NCT06148025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral Capsule
Description: 500mg every 6 hours for 3 days
Study NCT05052619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preventive use of advanced antibiotics
Description: Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
Study NCT06148025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin Oral Product
Description: 1000mg every 6 hours for 3 days
Study NCT06366321 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: relining technique
Description: construction of complete denture by flasking and casting the relining impression
Study NCT06366321 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CAD/CAM milling technique
Description: construction of complete denture by milling of the scanned relining impression
Study NCT05019300 — intervention group
Intervention type: BIOLOGICAL
Intervention: Exposure: COVID-19 severity
Description: COVID-19 severity between 4 to 7 points according the seven-category scale of clinical status reported by Huang et al. (2021) and severe to critical symptomatic levels on spectrum of disease reported by Wu and McGoogan (2020).
Study NCT05624398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivity IOL
Description: Cataract surgery with implantation of the Vivity IOL along with concurrent implantation of the Hydrus Microstent
Study NCT05704504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based exercise intervention with EMA and personalized telephone support (SUP)
Description: Participants in the SUP group will receive a 6-week group-based exercise intervention with EMA and personalized telephone support. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer and three 15-minute personalized telephone sessions delivered by research personnel. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and third group exercise sessions will include (1) reviewing exercise goals and EMA data, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
Study NCT05704504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based exercise intervention (EXE)
Description: Participants in the EXE group will receive a 6-week group-based exercise intervention. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer at the Chinese University of Hong Kong. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and the third group exercise sessions will include (1) reviewing exercise goals, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
Study NCT04741074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
Description: Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
Study NCT04741074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Description: Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
Study NCT05052619 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine
Description: Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
Study NCT05703594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: performance based balance test
Description: Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
Study NCT04782947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeletal assisted walking
Description: Exoskeletal assisted walking includes the use of robotic suit to train participant to walk with different level of assistance.
Study NCT04782947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulation
Description: lumbo-sacral epidural simulation at the beginning of the study.
Study NCT04782947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Using two forms of resistance training to increase muscle size. The first form includes seated leg extension exercise for 12 weeks followed by a second form that includes sit-to-stand exercise using participant's body weight.
Study NCT04782947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delayed-ES
Description: lumbo-sacral epidural simulation starting 6 months after the beginning of the study.
Study NCT04782947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-Resistance training
Description: The participants will perform 24 weeks of passive movement or passive stretching from seated position.
Study NCT05475119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
Study NCT05475119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Description: High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
Study NCT05007912 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagojejunostomy type
Description: Use of either circular or linear stapler
Study NCT06232551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR (electronic health record) alert
Description: Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis
Study NCT06232551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No EHR (electronic health record) alert
Description: During the baseline phase while risk is assessed and stored, no alerting occurs
Study NCT04841005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Square-Step Exercise Training
Description: The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 \* 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
Study NCT04841005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening Exercise Training
Description: Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
Study NCT05547828 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tislelizumab combined with chemoradiotherapy
Description: Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)
Study NCT06752096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cerebral angiography, arterial embolization, thrombectomy
Description: This intervention will be conducted using robotic navigation.
Study NCT06752096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral angiogram using robotic device
Description: Diagnostic cerebral angiogram will be performed using a robot to navigate guidewires and catheters to target vessels.
Study NCT06752096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meningioma embolization using robotic device.
Description: Meningioma tumors will be embolized using a robot to navigate catheters and wires to the target vessels to the tumor.
Study NCT06752096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy for stroke using a robotic device.
Description: Mechanical thrombectomy procedure will use a robot to navigate catheters, guidewires, and thrombectomy devices to the target vessel.